Five-year overall survival of pembrolizumab in advanced non-small cell lung cancer: another step from care to cure?

Affiliations

Editorial

Paolo Bironzo et al. Ann Transl Med. 2019 Sep.

. 2019 Sep;7(Suppl 6):S212.

doi: 10.21037/atm.2019.08.91.

¹ Department of Oncology, University of Torino, AOU S. Luigi Gonzaga, Orbassano, Italy.

No abstract available

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

Is there hope in improving 5-year overall survival?-review of 5-year overall survival data from KEYNOTE-001.
Akingbemi W, Garon E. Akingbemi W, et al. Ann Transl Med. 2020 Jun;8(11):728. doi: 10.21037/atm-2020-95. Ann Transl Med. 2020. PMID: 32617347 Free PMC article. No abstract available.

Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study.
Garon EB, Hellmann MD, Rizvi NA, Carcereny E, Leighl NB, Ahn MJ, Eder JP, Balmanoukian AS, Aggarwal C, Horn L, Patnaik A, Gubens M, Ramalingam SS, Felip E, Goldman JW, Scalzo C, Jensen E, Kush DA, Hui R. Garon EB, et al. J Clin Oncol. 2019 Oct 1;37(28):2518-2527. doi: 10.1200/JCO.19.00934. Epub 2019 Jun 2. J Clin Oncol. 2019. PMID: 31154919 Free PMC article. Clinical Trial.

1. Hall SS. A common in the blood: life, death, and the immune system. 1st edition. New York: Henry Holt & Co., 1997.
1. Garon EB, Hellmann MD, Rizvi NA, et al. Five-Year Overall Survival for Patients With Advanced Non-Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study. J Clin Oncol 2019. [Epub ahead of print]. 10.1200/JCO.19.00934 - DOI - PMC - PubMed
1. Topalian SL, Hodi FS, Brahmer JR, et al. Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non-Small Cell Lung Cancer Treated With Nivolumab. JAMA Oncol 2019. [Epub ahead of print]. 10.1001/jamaoncol.2019.2187 - DOI - PMC - PubMed
1. Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med 2016;375:1823-33. 10.1056/NEJMoa1606774 - DOI - PubMed
1. Gandhi L, Rodríguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. N Engl J Med 2018;378:2078-92. 10.1056/NEJMoa1801005 - DOI - PubMed